Incidence of venous thromboembolism (VTE) is more common in cancer
patients compared to non-cancer patients. Various factors that influence the incidence
of VTE are patient population, duration of follow-up, patient-related factors, type and
stage of tumor, chemotherapy agent or the treatment modality used, presence of central
venous catheters, detection methods, and reporting. Mortality is increased by various
factors such as delay or withdrawal of chemotherapy treatment, directly VTE-related
complications like pulmonary embolism. Development of VTE within 2 years was
found to be a significant risk factor for increased mortality and the rate was high among
patients with localized disease. For the prevention of VTE in patients with cancer
LMWH is given increased consideration, specifically Dalteparin [26, 27]. Further
studies are necessary to determine the effectiveness of thromboprophylaxis in the
reduction of mortality or thromboembolic complications in these high-risk populations.
Keywords: Cancer-associated thrombosis, Incidence of VTE in cancer, Mortality
due to VTE, Recurrent VTE, Thrombosis in ALL, Thrombosis in malignancy,
VTE prevention, VTE risks.
